Navigation Links
JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
Date:8/5/2010

CLEVELAND, Aug. 5 /PRNewswire/ -- JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO )

(Logo:  http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO )

Atrial fibrillation is characterized by an irregular beating of the heart caused by misfiring of electrical impulses. The abnormal contracting causes decreased cardiac function, raising the risk of stroke and heart failure. An oral form of ChanRx's anti-arrhythmia drug, called Vanoxerine, has already demonstrated its ability to restore normal heart rhythm in a human clinical study. The study also showed an improved safety profile, as compared to other drugs in the market or currently in development. 

ChanRx, which is a spin-out from parent company ChanTest, will use a majority of the funding and the entrepreneurial development assistance provided by JumpStart Venture Partner, Kevin Mendelsohn, to complete development of an intravenous formulation of Vanoxerine. The intravenous formulation will enable quicker absorption and increased speed to efficacy when compared to other deliveries of the drug.  

"Drug therapy is the mainstay of treatment for this condition; unfortunately, the drugs used today have delivered unsatisfactory efficacy and undesirable safety profiles, including links to potentially lethal arrhythmias," said Arthur "Buzz" Brown, Founder of ChanRx. "ChanRx's pharmaceutical compound has demonstrated a superior safety profile in six previously conducted Phase I human clinical trials. We also showed in a Phase IIa trial that oral Vanoxerine is effective in restoration of normal cardiac rhythm. Taking the drug from an oral to an IV formulation will improve its effectiveness and this investment from JumpStart Ventures provides us with the resources and assistance we need to accelerate that process."

This investment represents JumpStart Ventures' 66th investment in its 49th company.

About ChanRx

ChanRx is a Cleveland-based drug development company focused on the commercialization of repurposed drug candidates. The company is a spin-out of ChanTest (www.chantest.com), a leading pharmaceutical testing service company which has developed the world's most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. ChanRx is developing an intravenous (IV) formulation of a drug to treat atrial fibrillation.

About JumpStart Ventures

JumpStart Ventures (www.jumpstartinc.org/ventures) invests in and forges partnerships with innovative, early-stage Northeast Ohio companies that have the potential to generate $30 to $50 million in revenues in five to seven years. It helps companies accelerate their time to venture-readiness by bundling guidance from experienced Venture Partners with seed investment capital. JumpStart Ventures is the investment arm of JumpStart Inc., a nationally recognized non-profit organization creating economic transformation by providing resources to entrepreneurs leading high potential early-stage companies.


'/>"/>
SOURCE JumpStart Ventures
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. JumpStart Invests in Checkpoint Surgical
2. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
3. Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures
4. BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff
5. iPierian Closes $22 Million Series B Financing Led By Google Ventures
6. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
7. Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC
8. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
9. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
10. 7 Health Ventures Invests in Tulip Medical
11. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... EU5 Magnetic Resonance Imaging (MRI) Systems Market Outlook to 2022 ... ... Outlook to 2022", provides key market data on the EU5 Magnetic ... of US dollars, volume (in units) and average prices (USD) within ... The report also provides company shares and distribution shares ...
(Date:2/20/2017)... 2017 Taiwan Biophotonic Co. (tBPC), a medical ... signs sensing solutions, today announced the CE Marking and ... oximeter, the oCare TM Pro 100, which is a ... devices space.  tBPC,s Wrist Pulse Oximeter, the ... and reliable method to measure and record heart rate ...
(Date:2/20/2017)... TEMPE, Ariz. , Feb. 20, 2017 /PRNewswire/ ... to the medical device industry, announced today that ... Vention Medical,s Device Manufacturing Services business.  ... bolsters its position as a leading services provider ... MedPlast,s acquisition will further expand the company,s ...
Breaking Medicine Technology:
(Date:2/20/2017)... ALEXANDRIA, VA (PRWEB) , ... February 20, 2017 , ... ... with Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, ... of 2018 on a site just outside of Old Town. , The three-story ...
(Date:2/20/2017)... ... 2017 , ... Researchers at the University of Pittsburgh School of Medicine have ... may predict response to a particular class of drugs, not just in patients with ... new findings were published in Proceedings of the National Academy of Science. , “These ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Biscom , the ... the first IoT device from Biscom designed to deliver confidential patient information securely ... at HIMSS17 and will be conducting demonstrations at Booth #374. ...
(Date:2/20/2017)... ... ... a Population Health Software Company, is pleased to announce a move to a larger office ... the size of the previous location while bringing life back to a medical practice building ... are excited to expand our footprint to better serve our growing client base. We ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center ... a joint event at Chuck E. Cheese’s locations throughout New England, New York and ... the opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly ...
Breaking Medicine News(10 mins):